HIFU for hemiablation of localized prostate cancer

A major plenary presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data from a rather small French trial of  high-intensity focused ultrasound (HIFU) in the focal management of localized prostate cancer. … READ MORE …

5-year outcomes from a large cohort of HIFU-treated patients in the UK

For several years now, the Ahmed/Emberton-led research team in the United Kingdom (UK) has published the majority of the detailed outcomes data from treatment of men with localized prostate cancer using high-intensity focused ultrasound (HIFU). This group has now given us 5-year outcomes on a cohort of > 550 patients. … READ MORE …

Data from a prospective trial of HIFU-based hemiablation for localized prostate cancer

A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium. … READ MORE …

The FDA’s perspective on the approval of HIFU in the USA

For those able to access the February 2016 issue of the AUA News, it carries an interesting article outlining the U.S. Food and Drug Administration’s perspective on exactly why the agency decided to approve two forms of high-intensity focused ultrasound (HIFU) technology for the transrectal ablation of prostate tissue. … READ MORE …

Focal therapy of just the index or primary lesion

A newly published paper in European Urology has provided us with data from one of the earliest, well-documented series of patients undergoing focal therapy of the index lesion from what is known to have been multifocal prostate cancer. … READ MORE …

FDA approves EDAP TMS’s Ablatherm technology for HIFU therapy

As predicted, the U.S. Food and Drug Administration apparently approved the Ablatherm brand of equipment for high-intensity focused ultrasound (HIFU) on November 9 for “the ablation of prostate tissue.” … READ MORE …

Focal HIFU is “sexual function sparing” in a cohort of 118 selected patients

A new paper in European Urology has suggested that men with localized prostate cancer who are treated by focal forms of high-intensity focused ultrasound (HIFU) have “a return to baseline International Index of Erectile Function — erectile and total International Index of Erectile Function scores” by 6 months after treatment which was maintained at 1 year. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,454 other followers